Company structure
The AdnaGen AG is a stock holding company whereby the shares are not yet traded in public.

Currently, the shareholder structure is composed as follows:
- OncoVista Inc., San Antonio, TX, USA
- BioMed Venture GmbH, Hanover, Germany
- Founders
- Private group of investors
- Rose Nominees Ltd., St. Peter Port, UK

Financing
AdnaGen was founded in 1999 first as a GmbH (limited company) and financed by Venture Capital as well as funds from the tbg (Technologiebeteiligungsgesellschaft, a Government-led organization) in the form of a "silent" participation". The tbg is a subsidiary of the government-owned 'Deutsche Ausgleichsbank' with emphasis on supplementary financing of start-up companies provided there is a lead investor

Furthermore, AdnaGen received governmental support in the form of R&D grants for the product area Rare Cell Detection & Analysis (tumor and prenatal diagnostics).

Investor relations contact
For any further information and questions related to an investment into AdnaGen please do not hesitate to contact Winfried Albert, Managing Director:

Phone: ++49 (0) 511 725 950-50
Fax: ++49 (0) 511 725 950-40
Mobile: ++49 171 69 58 053
e-mail: wa@adnagen.com